BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

843 related articles for article (PubMed ID: 31109331)

  • 21. Overexpression of PDK2 and PDK3 reflects poor prognosis in acute myeloid leukemia.
    Cui L; Cheng Z; Liu Y; Dai Y; Pang Y; Jiao Y; Ke X; Cui W; Zhang Q; Shi J; Fu L
    Cancer Gene Ther; 2020 Feb; 27(1-2):15-21. PubMed ID: 30578412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of PAK family kinases in acute myeloid leukemia.
    Quan L; Cheng Z; Dai Y; Jiao Y; Shi J; Fu L
    Cancer Gene Ther; 2020 Feb; 27(1-2):30-37. PubMed ID: 30890765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High expression levels of SMAD3 and SMAD7 at diagnosis predict poor prognosis in acute myeloid leukemia patients undergoing chemotherapy.
    Zhang J; Zhang L; Cui H; Zhang X; Zhang G; Yang X; Yang S; Zhang Z; Wang J; Hu K; Shi J; Ke X; Fu L
    Cancer Gene Ther; 2019 May; 26(5-6):119-127. PubMed ID: 30177817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expression level of Neuronal Calcium Sensor 1 can predict the prognosis of cytogenetically normal AML.
    Zhang W; Wang J; Li W; Liu X; Zhao Y; Yang P; Zhu M; Hu K; Li S; Dong G; Yan C; He X; Zhang X; Jing H
    Pharmacogenomics J; 2023 Jul; 23(4):89-94. PubMed ID: 36918700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia.
    Zhou JD; Zhang TJ; Xu ZJ; Gu Y; Ma JC; Li XX; Guo H; Wen XM; Zhang W; Yang L; Liu XH; Lin J; Qian J
    Diagn Pathol; 2019 Jun; 14(1):68. PubMed ID: 31253168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
    Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
    J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
    Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
    J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High expression of AK1 predicts inferior prognosis in acute myeloid leukemia patients undergoing chemotherapy.
    Qin T; Zhao H; Shao Y; Hu N; Shi J; Fu L; Zhang Y
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32519744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic role of ACTL10 in Cytogenetic Normal Acute Myeloid Leukemia.
    Lai R; Zhang W; He X; Liao X; Liu X; Fu W; Yang P; Wang J; Hu K; Yuan X; Zhang X; Jing H; Liu W
    J Cancer; 2020; 11(17):5150-5161. PubMed ID: 32742462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia.
    Zhang H; Zhang N; Wang R; Shao T; Feng Y; Yao Y; Wu Q; Zhu S; Cao J; Zhang H; Li Z; Liu X; Niu M; Xu K
    J Transl Med; 2019 Apr; 17(1):106. PubMed ID: 30935386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations.
    Zhou L; An J; Hou C; Ding Z; Qiu H; Tang X; Sun A; Chen S; Xu Y; Liu T; Wu D
    Hematology; 2021 Dec; 26(1):340-347. PubMed ID: 33840380
    [No Abstract]   [Full Text] [Related]  

  • 32. Identification of A-kinase interacting protein 1 as a potential biomarker for risk and prognosis of acute myeloid leukemia.
    Yan Y; Li X; Gao J
    J Clin Lab Anal; 2020 May; 34(5):e23055. PubMed ID: 32356617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High expression of miR-338 is associated with poor prognosis in acute myeloid leukemia undergoing chemotherapy.
    Fu L; Qi J; Gao X; Zhang N; Zhang H; Wang R; Xu L; Yao Y; Niu M; Xu K
    J Cell Physiol; 2019 Nov; 234(11):20704-20712. PubMed ID: 30997674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions.
    Fu L; Fu H; Wu Q; Pang Y; Xu K; Zhou L; Qiao J; Ke X; Xu K; Shi J
    J Transl Med; 2017 Jul; 15(1):159. PubMed ID: 28724426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct association of RUNX family expression with genetic alterations and clinical outcome in acute myeloid leukemia.
    Zhao Y; Zhang T; Zhao Y; Zhou J
    Cancer Biomark; 2020; 29(3):387-397. PubMed ID: 32741803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
    Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
    Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
    Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
    J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.
    Duployez N; Marceau-Renaut A; Villenet C; Petit A; Rousseau A; Ng SWK; Paquet A; Gonzales F; Barthélémy A; Leprêtre F; Pottier N; Nelken B; Michel G; Baruchel A; Bertrand Y; Leverger G; Lapillonne H; Figeac M; Dick JE; Wang JCY; Preudhomme C; Cheok M
    Leukemia; 2019 Feb; 33(2):348-357. PubMed ID: 30089916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome.
    Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Guo R; Tierens A; Minden MD; Chang H
    Hum Pathol; 2020 Oct; 104():117-126. PubMed ID: 32798550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.
    Fu L; Shi J; Hu K; Wang J; Wang W; Ke X
    Oncotarget; 2015 Apr; 6(10):8144-54. PubMed ID: 25924238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.